13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity )
Also on site :
- 80s Metal Icons Play Epic First UK Show in 6 Years Ahead of Black Sabbath Opener
- Freddy Galvis Announces Retirement
- Mel Owens' Ex-Wife Issues Bold Statement on His Upcoming 'Golden Bachelor' Season: 'It's Going to be Bad'